0001752724-23-272094.txt : 20231129 0001752724-23-272094.hdr.sgml : 20231129 20231128180127 ACCESSION NUMBER: 0001752724-23-272094 CONFORMED SUBMISSION TYPE: NPORT-P PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230929 FILED AS OF DATE: 20231129 DATE AS OF CHANGE: 20231128 PERIOD START: 20240630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Virtus Investment Trust CENTRAL INDEX KEY: 0000867297 IRS NUMBER: 330457728 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: NPORT-P SEC ACT: 1940 Act SEC FILE NUMBER: 811-06161 FILM NUMBER: 231447831 BUSINESS ADDRESS: STREET 1: 101 MUNSON STEET CITY: GREENFIELD STATE: MA ZIP: 01301 BUSINESS PHONE: 800-243-1574 MAIL ADDRESS: STREET 1: ONE FINANCIAL PLAZA STREET 2: 26TH FLOOR CITY: HARTFORD STATE: CT ZIP: 06103 FORMER COMPANY: FORMER CONFORMED NAME: ALLIANZ FUNDS DATE OF NAME CHANGE: 20050330 FORMER COMPANY: FORMER CONFORMED NAME: PIMCO FUNDS MULTI MANAGER SERIES DATE OF NAME CHANGE: 19970626 FORMER COMPANY: FORMER CONFORMED NAME: PIMCO FUNDS EQUITY ADVISORS SERIES DATE OF NAME CHANGE: 19960227 0000867297 S000007977 Virtus KAR Health Sciences Fund C000021683 A RAGHX C000021685 C RCGHX C000150255 Institutional Class HLHIX C000220799 P AAAEX NPORT-P 1 primary_doc.xml NPORT-P false 0000867297 XXXXXXXX S000007977 C000021685 C000220799 C000021683 C000150255 Virtus Investment Trust 811-06161 0000867297 549300JFX7YJRKFQYL29 101 Munson Street Greenfield 01301-9668 800-243-1574 Virtus KAR Health Sciences Fund S000007977 549300SFFVE67D5VU641 2024-06-30 2023-09-29 N 138458352.49 198739.77 138259612.72 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 837887.04000000 N STAAR Surgical Co 5299006LRHI7OJ8BY308 STAAR Surgical Co 852312305 76067.00000000 NS USD 3056372.06000000 2.210603660658 Long EC CORP US N 1 N N N Bristol-Myers Squibb Co HLYYNH7UQUORYSJQCN42 Bristol-Myers Squibb Co 110122108 67584.00000000 NS USD 3922575.36000000 2.837108597970 Long EC CORP US N 1 N N N McKesson Corp 549300WZWOM80UCFSF54 McKesson Corp 58155Q103 14263.00000000 NS USD 6202265.55000000 4.485956113995 Long EC CORP US N 1 N N N Zoetis Inc 549300HD9Q1LOC9KLJ48 Zoetis Inc 98978V103 36982.00000000 NS USD 6434128.36000000 4.653657155130 Long EC CORP US N 1 N N N Pfizer Inc 765LHXWGK1KXCLTFYQ30 Pfizer Inc 717081103 130658.00000000 NS USD 4333925.86000000 3.134628959779 Long EC CORP US N 1 N N N Align Technology Inc 549300N5YSE0U3LCP840 Align Technology Inc 016255101 11747.00000000 NS USD 3586594.04000000 2.594101031704 Long EC CORP US N 1 N N N West Pharmaceutical Services I 5493007NKRGM1RJQ1P16 West Pharmaceutical Services Inc 955306105 18458.00000000 NS USD 6925626.18000000 5.009146231318 Long EC CORP US N 1 N N N Insulet Corp 549300TZTYD2PYN92D43 Insulet Corp 45784P101 12953.00000000 NS USD 2065873.97000000 1.494199158639 Long EC CORP US N 1 N N N AbbVie Inc FR5LCKFTG8054YNNRU85 AbbVie Inc 00287Y109 45206.00000000 NS USD 6738406.36000000 4.873734438737 Long EC CORP US N 1 N N N Moderna Inc 549300EI6OKH5K5Q2G38 Moderna Inc 60770K107 24716.00000000 NS USD 2552915.64000000 1.846465203956 Long EC CORP US N 1 N N N HealthEquity Inc 529900LRJU1RAFQHM467 HealthEquity Inc 42226A107 52119.00000000 NS USD 3807292.95000000 2.753727480569 Long EC CORP US N 1 N N N Amgen Inc 62QBXGPJ34PQ72Z12S66 Amgen Inc 031162100 9936.00000000 NS USD 2670399.36000000 1.931438478283 Long EC CORP US N 1 N N N Charles River Laboratories Int 549300BSQ0R4UZ5KX287 Charles River Laboratories International Inc 159864107 15264.00000000 NS USD 2991438.72000000 2.163638868320 Long EC CORP US N 1 N N N Thermo Fisher Scientific Inc HCHV7422L5HDJZCRFL38 Thermo Fisher Scientific Inc 883556102 10165.00000000 NS USD 5145218.05000000 3.721417953354 Long EC CORP US N 1 N N N Merck & Co Inc 4YV9Y5M8S0BRK1RP0397 Merck & Co Inc 58933Y105 55571.00000000 NS USD 5721034.45000000 4.137892720404 Long EC CORP US N 1 N N N US Physical Therapy Inc 529900KL1UXQYFIOMY96 US Physical Therapy Inc 90337L108 47329.00000000 NS USD 4341489.17000000 3.140099328060 Long EC CORP US N 1 N N N Vertex Pharmaceuticals Inc 54930015RAQRRZ5ZGJ91 Vertex Pharmaceuticals Inc 92532F100 14743.00000000 NS USD 5126730.82000000 3.708046564821 Long EC CORP US N 1 N N N IDEXX Laboratories Inc OGMTXK0LUU1HKV2P0J84 IDEXX Laboratories Inc 45168D104 12881.00000000 NS USD 5632474.87000000 4.073839611721 Long EC CORP US N 1 N N N Cooper Cos Inc/The QJKMVPIGLH7530PCUE20 Cooper Cos Inc/The 216648402 18500.00000000 NS USD 5883185.00000000 4.255172486208 Long EC CORP US N 1 N N N STERIS PLC N/A STERIS PLC 000000000 15198.00000000 NS USD 3334745.16000000 2.411944525516 Long EC CORP US N 1 N N N UnitedHealth Group Inc 549300GHBMY8T5GXDE41 UnitedHealth Group Inc 91324P102 13808.00000000 NS USD 6961855.52000000 5.035350080213 Long EC CORP US N 1 N N N Regeneron Pharmaceuticals Inc 549300RCBFWIRX3HYQ56 Regeneron Pharmaceuticals Inc 75886F107 4263.00000000 NS USD 3508278.48000000 2.537457187229 Long EC CORP US N 1 N N N Teleflex Inc UUL85LWXB4NGSWWXIQ25 Teleflex Inc 879369106 10100.00000000 NS USD 1983741.00000000 1.434794269254 Long EC CORP US N 1 N N N Mettler-Toledo International I 5493000BD5GJNUDIUG10 Mettler-Toledo International Inc 592688105 4314.00000000 NS USD 4780213.98000000 3.457418899097 Long EC CORP US N 1 N N N Azenta Inc 35ZN6X1ANPH25YN32Y17 Azenta Inc 114340102 85530.00000000 NS USD 4292750.70000000 3.104847912957 Long EC CORP US N 1 N N N Danaher Corp S4BKK9OTCEWQ3YHPFM11 Danaher Corp 235851102 24615.00000000 NS USD 6106981.50000000 4.417039350723 Long EC CORP US N 1 N N N Intuitive Surgical Inc 54930052SRG011710797 Intuitive Surgical Inc 46120E602 10543.00000000 NS USD 3081613.47000000 2.228860192340 Long EC CORP US N 1 N N N Eli Lilly & Co FRDRIPF3EKNDJ2CQJL29 Eli Lilly & Co 532457108 23626.00000000 NS USD 12690233.38000000 9.178554120283 Long EC CORP US N 1 N N N Edwards Lifesciences Corp YA13X31F3V31L8TMPR58 Edwards Lifesciences Corp 28176E108 48272.00000000 NS USD 3344284.16000000 2.418843864963 Long EC CORP US N 1 N N N 2023-11-20 Virtus Investment Trust Amy Hackett Amy Hackett Vice President and Assistant Treasurer XXXX NPORT-EX 2 VIAB040VIRTUS093023.htm
VIRTUS KAR Health Sciences Fund
SCHEDULE OF INVESTMENTS (Unaudited)
September 30, 2023
($ reported in thousands)
  Shares   Value
Common Stocks—99.3%
Biotechnology—14.9%    
AbbVie, Inc.  45,206   $  6,739
Amgen, Inc.   9,936     2,670
Moderna, Inc.(1)  24,716     2,553
Regeneron Pharmaceuticals, Inc.(1)   4,263     3,508
Vertex Pharmaceuticals, Inc.(1)  14,743     5,127
       20,597
       
 
Healthcare Equipment &
Supplies—23.1%
   
Align Technology, Inc.(1)  11,747     3,587
Cooper Cos., Inc. (The)  18,500     5,883
Edwards Lifesciences Corp.(1)  48,272     3,344
IDEXX Laboratories, Inc.(1)  12,881     5,632
Insulet Corp.(1)  12,953     2,066
Intuitive Surgical, Inc.(1)  10,543     3,082
STAAR Surgical Co.(1)  76,067     3,056
STERIS plc  15,198     3,335
Teleflex, Inc.  10,100     1,984
       31,969
       
 
  Shares   Value
       
Healthcare Providers &
Services—15.4%
   
HealthEquity, Inc.(1)  52,119   $  3,807
McKesson Corp.  14,263     6,202
U.S. Physical Therapy, Inc.  47,329     4,342
UnitedHealth Group, Inc.  13,808     6,962
       21,313
       
 
Life Sciences Tools & Services—21.9%    
Azenta, Inc.(1)  85,530     4,293
Charles River Laboratories International, Inc.(1)  15,264     2,991
Danaher Corp.  24,615     6,107
Mettler-Toledo International, Inc.(1)   4,314     4,780
Thermo Fisher Scientific, Inc.  10,165     5,145
West Pharmaceutical Services, Inc.  18,458     6,926
       30,242
       
 
Pharmaceuticals—24.0%    
Bristol-Myers Squibb Co.  67,584     3,923
Eli Lilly & Co.  23,626    12,690
Merck & Co., Inc.  55,571     5,721
Pfizer, Inc. 130,658     4,334
  Shares   Value
       
Pharmaceuticals—continued    
Zoetis, Inc. Class A  36,982   $  6,434
       33,102
       
 
Total Common Stocks
(Identified Cost $135,513)
  137,223
       
 
       
 
Total Long-Term Investments—99.3%
(Identified Cost $135,513)
  137,223
       
 
       
 
TOTAL INVESTMENTS—99.3%
(Identified Cost $135,513)
  $137,223
Other assets and liabilities, net—0.7%     1,031
NET ASSETS—100.0%   $138,254
    
Footnote Legend:
(1) Non-income producing.
The following table summarizes the value of the Fund’s investments as of September 30, 2023, based on the inputs used to value them (See Security Valuation Note 1 in the Notes to Schedule of Investments):
  Total
Value at
September 30, 2023
  Level 1
Quoted Prices
Assets:      
Equity Securities:      
Common Stocks $137,223   $137,223
Total Investments $137,223   $137,223
There were no securities valued using significant observable inputs (Level 2) or significant unobservable inputs (Level 3) at September 30, 2023.
There were no transfers into or out of Level 3 related to securities held at September 30, 2023.
See Notes to Schedule of Investments
1

VIRTUS KAR Health Sciences Fund
NOTES TO SCHEDULE OF INVESTMENTS (Unaudited)
September 30, 2023
Note 1. Security Valuation
The Fund’s Board of Trustees have designated the Investment Adviser as the valuation designee to perform fair valuations pursuant to Rule 2a-5 under the Investment Company Act of 1940. The Fund utilizes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The Fund’s policy is to recognize transfers into or out of Level 3 at the end of the reporting period.
Level 1 – quoted prices in active markets for identical securities (security types generally include listed equities).
Level 2 – prices determined using other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
Level 3 – prices determined using significant unobservable inputs (including the Investment Adviser’s Valuation Committee’s own assumptions in determining the fair value of investments).
A description of the valuation techniques applied to the Fund’s major categories of assets and liabilities measured at fair value on a recurring basis is as follows:
Equity securities are valued at the official closing price (typically last sale) on the exchange on which the securities are primarily traded or, if no closing price is available, at the last bid price and are categorized as Level 1 in the hierarchy. Illiquid, restricted equity securities and illiquid private placements are internally fair valued by the Investment Adviser’s Valuation Committee, and are generally categorized as Level 3 in the hierarchy.
Certain non-U.S. securities may be fair valued in cases where closing prices are not readily available or are deemed not reflective of readily available market prices. For example, significant events (such as movement in the U.S. securities market, or other regional and local developments) may occur between the time that non-U.S. markets close (where the security is principally traded) and the time that the Fund calculates its net asset value (“NAV”) at the close of regular trading on the New York Stock Exchange (“NYSE”) (generally 4 p.m. Eastern time) that may impact the value of securities traded in these non-U.S. markets. In such cases, the Fund fair values non-U.S. securities using an independent pricing service which considers the correlation of the trading patterns of the non-U.S. security to the intraday trading in the U.S. markets for investments such as American Depositary Receipts, financial futures, Exchange-Traded Funds (“ETFs”), and certain indexes, as well as prices for similar securities. Such fair valuations are categorized as Level 2 in the hierarchy. Because the frequency of significant events is not predictable, fair valuation of certain non-U.S. common stocks may occur on a frequent basis.
Debt instruments, including convertible bonds, and restricted securities, are valued based on evaluated quotations received from independent pricing services or from dealers who make markets in such securities. For most bond types, the pricing service utilizes matrix pricing that considers one or more of the following factors: yield or price of bonds of comparable quality, coupon, maturity, current cash flows, type, activity of the underlying equities, and current day trade information, as well as dealer supplied prices. These valuations are generally categorized as Level 2 in the hierarchy. Structured debt instruments, such as mortgage-backed and asset-backed securities may also incorporate collateral analysis and utilize cash flow models for valuation and are generally categorized as Level 2 in the hierarchy. Pricing services do not provide pricing for all securities and therefore indicative bids from dealers are utilized which are based on pricing models used by market makers in the security and are generally categorized as Level 2 in the hierarchy. Debt instruments that are internally fair valued by the Investment Adviser’s Valuation Committee are generally categorized as Level 3 in the hierarchy.
Listed derivatives, such as options, that are actively traded are valued at the last posted settlement price from the exchange where they are principally traded and are categorized as Level 1 in the hierarchy. Over-the-counter derivative contracts, which include forward currency contracts and equity-linked instruments, do not require material subjectivity as pricing inputs are observed from actively quoted markets and are categorized as Level 2 in the hierarchy.
Investments in open-end mutual funds are valued at NAV. Investments in closed-end funds and ETFs are valued as of the close of regular trading on the NYSE each business day. Each is categorized as Level 1 in the hierarchy.
A summary of the inputs used to value the Fund’s net assets by each major security type is disclosed at the end of the Schedule of Investments for the Fund. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
For additional information about significant accounting policies, refer to the Fund’s most recent semi or annual report.
2